CN107375821A - A kind of Chinese medicine composition is preparing the application in protecting vascular endothelial cell medicine - Google Patents
A kind of Chinese medicine composition is preparing the application in protecting vascular endothelial cell medicine Download PDFInfo
- Publication number
- CN107375821A CN107375821A CN201610323079.0A CN201610323079A CN107375821A CN 107375821 A CN107375821 A CN 107375821A CN 201610323079 A CN201610323079 A CN 201610323079A CN 107375821 A CN107375821 A CN 107375821A
- Authority
- CN
- China
- Prior art keywords
- endothelial cell
- fruit
- glossy privet
- gained
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 210000003556 vascular endothelial cell Anatomy 0.000 title description 3
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 60
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000005482 chemotactic factor Substances 0.000 claims abstract description 37
- 230000006378 damage Effects 0.000 claims abstract description 27
- 230000014509 gene expression Effects 0.000 claims abstract description 27
- 210000003606 umbilical vein Anatomy 0.000 claims abstract description 6
- 230000028327 secretion Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 241000830535 Ligustrum lucidum Species 0.000 claims description 37
- 235000013399 edible fruits Nutrition 0.000 claims description 37
- 241000208340 Araliaceae Species 0.000 claims description 28
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 28
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 28
- 235000008434 ginseng Nutrition 0.000 claims description 28
- 241001233914 Chelidonium majus Species 0.000 claims description 25
- 240000009138 Curcuma zedoaria Species 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 25
- 241000287828 Gallus gallus Species 0.000 claims description 23
- 244000197580 Poria cocos Species 0.000 claims description 23
- 235000008599 Poria cocos Nutrition 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 21
- 239000000341 volatile oil Substances 0.000 claims description 21
- 241000132012 Atractylodes Species 0.000 claims description 20
- 210000004317 gizzard Anatomy 0.000 claims description 20
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 18
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 18
- 240000001851 Artemisia dracunculus Species 0.000 claims description 18
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 18
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 18
- 241000208365 Celastraceae Species 0.000 claims description 18
- 244000169544 Duchesnea indica Species 0.000 claims description 18
- 240000008397 Ganoderma lucidum Species 0.000 claims description 18
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 18
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 18
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 18
- 239000009636 Huang Qi Substances 0.000 claims description 18
- 235000000336 Solanum dulcamara Nutrition 0.000 claims description 18
- 239000001138 artemisia absinthium Substances 0.000 claims description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 18
- 240000001659 Oldenlandia diffusa Species 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 12
- -1 filter Substances 0.000 claims description 12
- 101800004490 Endothelin-1 Proteins 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 210000003038 endothelium Anatomy 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 102100033902 Endothelin-1 Human genes 0.000 claims 1
- 240000002853 Nelumbo nucifera Species 0.000 claims 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 239000000126 substance Substances 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 8
- 102000005962 receptors Human genes 0.000 abstract description 2
- 108020003175 receptors Proteins 0.000 abstract description 2
- 230000000711 cancerogenic effect Effects 0.000 abstract 2
- 231100000315 carcinogenic Toxicity 0.000 abstract 2
- 102000030168 Endothelin A Receptor Human genes 0.000 abstract 1
- 108010090549 Endothelin A Receptor Proteins 0.000 abstract 1
- 230000003466 anti-cipated effect Effects 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 32
- 244000309469 Human enteric coronavirus Species 0.000 description 18
- 235000005911 diet Nutrition 0.000 description 18
- 230000037213 diet Effects 0.000 description 18
- 235000014375 Curcuma Nutrition 0.000 description 17
- 244000164480 Curcuma aromatica Species 0.000 description 17
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 17
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 17
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 17
- 235000019509 white turmeric Nutrition 0.000 description 17
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 12
- 102400000686 Endothelin-1 Human genes 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 8
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102000009410 Chemokine receptor Human genes 0.000 description 7
- 108050000299 Chemokine receptor Proteins 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 5
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 5
- 239000000370 acceptor Substances 0.000 description 5
- 230000003399 chemotactic effect Effects 0.000 description 5
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 5
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 4
- 102100023705 C-C motif chemokine 14 Human genes 0.000 description 4
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 4
- 108050009340 Endothelin Proteins 0.000 description 4
- 102000002045 Endothelin Human genes 0.000 description 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 4
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 4
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 4
- 101000746022 Homo sapiens CX3C chemokine receptor 1 Proteins 0.000 description 4
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 3
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 3
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 3
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 3
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 3
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 3
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 2
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 2
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 2
- 108091008925 CX3C chemokine receptors Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 2
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 2
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091008926 C chemokine receptors Proteins 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100034673 C-C motif chemokine 3-like 1 Human genes 0.000 description 1
- 108091008927 CC chemokine receptors Proteins 0.000 description 1
- 102000005674 CCR Receptors Human genes 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000946370 Homo sapiens C-C motif chemokine 3-like 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- UZIQYAYUUNMDMU-UHFFFAOYSA-N N.[Br+] Chemical compound N.[Br+] UZIQYAYUUNMDMU-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 241000157511 Oldenlandia Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 101150022630 prp5 gene Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of application of Chinese medicine composition in the medicine for preparing protection endothelial cell, experiment is confirmed after being handled by carcinogenic chemical and/or mechanical damage Human Umbilical Vein Endothelial Cells, can Human Umbilical Vein Endothelial Cells produce infringement, cell chemotactic factor and expression of receptor is caused to lack of proper care, endothelial cell after being anticipated using the Chinese medicine composition, handled again by carcinogenic chemical and/or mechanical damage Human Umbilical Vein Endothelial Cells, it was found that Chinese medicine composition of the present invention can significantly improve the expression imbalance of the endothelial cell chemotactic factor and acceptor, endothelial cell existence activity is improved simultaneously, promote growing multiplication, increase nitric oxide (NO) secretion, reduce Endothelin receptor A (ET 1) expression, improve endothelial cells secrete function.Therefore it can be confirmed that Chinese medicine composition of the present invention can effectively protect endothelial cell.
Description
Technical field
The present invention relates to a kind of pharmaceutical applications of Chinese medicine composition, specifically, being related to the Chinese medicine composition is preparing protection
Application in endothelial cell medicine.
Background technology
Endothelial cell, some being distributed across in brain, lymph node, lung, liver, spleen etc. organ-tissue have common feature
Phagocyte general name, they swallow foreign matter, bacterium, necrosis and the tissue of aging, also participate in collective Immunization Activities.Endothelium is thin
Born of the same parents can synthesize and secrete various bioactivators, adjust body function.
Chemotactic factor (CF) is the small cytokines for being capable of the movement of chemotactic cell directional, and first chemotactic was found from 1988
Since factor CCL2 (MCP21), the structure of chemotactic factor (CF) and its acceptor, function and effect in vivo have become numerous
The focus of person's research.The interaction of chemotactic factor (CF) and its acceptor participates in growth, development, differentiation, apoptosis and distribution of cell etc.
Different physiological roles, and being played a significant role in a variety of pathologic processes, as inflammatory reaction, pathogenic infection, wound repair and
Tumour formation and transfer etc..
Chemotactic factor (CF) is small molecule basic protein, is made up of 70-125 amino acid, molecular weight 6-14kD.So far
At least have found that more than 50 plant chemotactic factor (CF) untill the present, can be by chemotactic factor (CF) according to the position of its N-terminal cysteine residues and number
It is divided into 4 subtribes:C, CC, CXC and CX3C.CC, CXC and CX3C chemotactic factor (CF) have 4 conservative cysteines, and C chemotactics because
Son only has 2 cysteines, equivalent to former three the 2nd and the position of the 4th cysteine.2 half Guang ammonia before CC chemotactic factor (CF)s
Sour neighbour, and 1 and 3 other amino acid are respectively separated before CXC and CX3C chemotactic factor (CF)s between 2 cysteines.It is most
Chemotactic factor (CF) belongs to CC and the races of CXC two, and the former has 28 members, and the latter includes 16 member's chemotactic factor (CF)s.
Chemotactic factor (CF) with the specific receptor of cell surface by combining the corresponding biological action of performance.Chemotactic factor (CF) by
Body category g protein coupled receptor, there are 7 membrane spanning segments, be mainly expressed in each WBC sub-population of derived from bone marrow, while also express
In on the cell of the types such as epithelial cell, vascular endothelial cell, nerve cell.The part that chemokine receptors is combined according to it is not
It is same to be also classified into 4 subfamilies:C chemokine receptors (XCR), CC chemokine receptors (CCR), Gro-beta-T
Acceptor (CXCR) and CX3C chemokine receptors (CX3CR).At least clone 18 kinds of chemokine receptors, wherein XCR at present
There is a kind, CCR10 kinds, CXCR6 kinds and CX3CR1 kinds.Some chemotactic factor (CF)s are specifically combined with a kind of acceptor, such as
CXCL12 (SDF21) is only combined with CXCR4;And some chemotactic factor (CF)s can be combined with several acceptors, such as CCL5
(RAN2TES) can be combined with CCR1, CCR3 and CCR5;It is equally sometimes a kind of to be combined by physical efficiency with several chemotactic factor (CF)s, such as,
CCR3 can combine a variety of chemotactic factor (CF)s such as CCL5, CCL7, CCL8, CCL24 and CCL26, this result cause a kind of chemotactic because
Son can express the immunocyte directional migration of different chemokine receptors with chemotactic, and a kind of immunocyte can also be it is a variety of become
Change the factor to be recruited.
Endothelin (ET) is the 21 amino acid groups of one kind isolated and purified out from the aortic endothelial cell of pig for 1988
Into vasoactive polypeptides.It is distributed mainly in kidney, liver, the heart, brain, sustainer and vein endothelial cell, is a kind of endogenous
Property often effect and potent vasoconstrictor, vessel retraction, platelet aggregation and smooth muscle cell proliferation can be caused.1980 first
It was found that endothelium-derived relaxing factor (EDRF) turned out to be nitric oxide (NO).It is thin from endothelial cell, cranial nerve
Born of the same parents, non-adrenal gland non-cholinergic neuronal epithelial cell (NANC) and by toxin, the macrophage and smooth muscle of cytokine activation
Cell.On the one hand NO has vasodilator effect, on the other hand as cell interior and the courier of intercellular trafficking biological information
Played a role under the pathological conditions such as ischemic.Endothelin and nitric oxide are all important endothelial factors.Research prompting blood plasma ET
The horizontal reacting condition coincident with severity degree of condition of ICVD.
The content of the invention
The present invention relates to a kind of new application of Chinese medicine composition, in particular it relates to which a kind of Chinese medicine composition is preparing protection
Application in endothelial cell medicine.
Chinese medicine of the present invention can be according to《National Chinese medicine preparation specification》Or《Dictionary of medicinal plant》Processed.The present invention
Medicine is made of the bulk drug of following weight ratio:
Radix Astragali 120-360, fruit of glossy privet 100-300, ginseng 30-95, ganoderma lucidum 30-95, curcuma zedoary 65-195, bighead atractylodes rhizome 30-90, Sculellaria barbata
65-195, gynostemma pentaphylla 120-360, Poria cocos 30-95, the membrane of a chicken's gizzard 15-45, mock-strawberry 65-195, bittersweet 65-195, oriental wormwood 65-195,
Paniculate swallowwort 65-195, ground bettle 10-30, oldenlandia diffusa 65-195.
Preferably, the Chinese medicine composition is made up of the bulk drug of following parts by weight:
The Radix Astragali 120, the fruit of glossy privet 300, ginseng 30, ganoderma lucidum 95, curcuma zedoary 65, the bighead atractylodes rhizome 90, Sculellaria barbata 65, gynostemma pentaphylla 360, Poria cocos 30,
The membrane of a chicken's gizzard 45, mock-strawberry 65, bittersweet 195, oriental wormwood 65, paniculate swallowwort 195, ground bettle 10, oldenlandia diffusa 195.
Or
The Radix Astragali 360, the fruit of glossy privet 100, ginseng 95, ganoderma lucidum 30, curcuma zedoary 195, the bighead atractylodes rhizome 30, Sculellaria barbata 195, gynostemma pentaphylla 120, Poria cocos
95th, the membrane of a chicken's gizzard 15, mock-strawberry 195, bittersweet 65, oriental wormwood 195, paniculate swallowwort 65, ground bettle 30, oldenlandia diffusa 65.
Or
The Radix Astragali 250, the fruit of glossy privet 200, ginseng 65, ganoderma lucidum 65, curcuma zedoary 132, the bighead atractylodes rhizome 64, Sculellaria barbata 128, gynostemma pentaphylla 256, Poria cocos
65th, the membrane of a chicken's gizzard 30, mock-strawberry 128, bittersweet 128, oriental wormwood 128, paniculate swallowwort 128, ground bettle 20, oldenlandia diffusa 128.
Preferably, in the raw materials used medicine of the Chinese medicine composition, the bighead atractylodes rhizome is rhizoma atractylodis macrocephalae.
Present invention also offers the active component of the Chinese medicine composition to be made up of following steps:
(1) Chinese medicine, is weighed according to bulk drug part by weight, is cleaned；
(2), the fruit of glossy privet, people participate in 6-10 times and measure 50-90% ethanol extraction 1-3 times, each 1-4 hours, merge extract solution, mistake
Filter, filtrate recycling ethanol are extremely standby without alcohol taste, filtrate and the dregs of a decoction；
(3), curcuma zedoary, the bighead atractylodes rhizome, paniculate swallowwort add 4-8 times to measure water extraction volatile oil, collect volatile oil, and another device is collected, residue and water-soluble
Liquid is standby；
(4), ground bettle, the membrane of a chicken's gizzard, Poria cocos are ground into fine powder；
(5) income earner in, the Radix Astragali, ganoderma lucidum, oldenlandia diffusa, Sculellaria barbata, gynostemma pentaphylla, mock-strawberry, bittersweet, oriental wormwood, with step (2)
Join, residue after the alcohol extracting of the fruit of glossy privet, and the middle gained curcuma zedoary of step (3), the bighead atractylodes rhizome, paniculate swallowwort propose residue merging after oil, add 7-10 times
Water is measured, heating decocts 1-3 times, each 1-3 hours, merges decoction liquor, adds gained ginseng in step (2), fruit of glossy privet alcohol extracting filter
Liquid and step（3）In the aqueous solution, be concentrated into decoction 65 DEG C survey when relative density be 1.15-1.30, dry, pulverize, it is standby；
Step（4）Gained comminuted powder, step（3）Gained volatile oil and step（5）The dried cream powder of gained collectively forms the Chinese medicine group
The active component of compound.
The formulation of medicine of the present invention is capsule, tablet, powder, oral liquid, soft capsule, pill, tincture, syrup, bolt
Agent, gel, spray or injection.
The wherein preparation method of capsule, is made up of following steps：
(1) Chinese medicine, is weighed according to bulk drug part by weight, is cleaned；
(2), ginseng, the fruit of glossy privet, 8 times of 70% alcohol refluxs of amount are added to extract 2 times, 3 hours for the first time, second 2 hours, merging carried
Liquid is taken, is filtered, recovery ethanol is extremely standby without alcohol taste, filtrate and ginseng, fruit of glossy privet residue；
(3), curcuma zedoary, the bighead atractylodes rhizome, paniculate swallowwort, merging extraction volatile oil, carry the oily time no less than 8 hours, the another device of volatile oil is collected,
Residue and the aqueous solution are standby；
(4), ground bettle, the taste animal drugs of the membrane of a chicken's gizzard two, washing, 60 DEG C of drying, merge with Poria cocos, be ground into 100 mesh powder, sterilize
It is standby afterwards；
(5) income earner in, the Radix Astragali, ganoderma lucidum, oldenlandia diffusa, Sculellaria barbata, gynostemma pentaphylla, mock-strawberry, bittersweet, oriental wormwood, with step (2)
Join, residue after the alcohol extracting of the fruit of glossy privet, and the middle gained curcuma zedoary of step (3), the bighead atractylodes rhizome, paniculate swallowwort propose residue merging after oil, add 9 times of amounts
Water, heating decoct 2 times, 2 hours every time, merge decoction liquor, add gained ginseng, fruit of glossy privet alcohol extracting filtrate and step in step (2)
Suddenly（3）In the aqueous solution, be condensed into relative density 1.20-1.25 clear cream, dry, pulverize, get dry extract powder；By gained dried cream powder
Add appropriate pharmaceutically acceptable auxiliary material granulation；
(6), gained volatile oil in step (3) is sprayed into the fine powder of the middle gained Poria cocos of step (4), ground bettle, the membrane of a chicken's gizzard, mixed
It is even, with step（5）The particle of middle gained mixes, closed half an hour, encapsulated to produce.
After other formulations of medicine of the present invention weigh bulk drug in proportion, prepared using the preparation method of routine, for example, model
Bi Ting《Pharmacy of Chinese materia medica》（Shanghai Science Press December the 1st edition in 1997）The preparation technology of record, pharmacy, which is made, to be connect
The regular dosage form received.
To enable above-mentioned formulation to realize, pharmaceutically acceptable auxiliary material need to be added when preparing these formulations, such as：Filling
Agent, disintegrant, lubricant, suspending agent, adhesive, sweetener, flavouring, preservative, matrix etc..Filler includes：It is starch, pre-
Gelling starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；Disintegrant includes：Starch, pregelatinized starch, crystallite
Cellulose, sodium carboxymethyl starch, PVPP, low-substituted hydroxypropyl cellulose, Ac-Di-Sol etc.；
Lubricant includes：Magnesium stearate, lauryl sodium sulfate, talcum powder, silica etc.；Suspending agent includes：Polyvinylpyrrolidine
Ketone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Adhesive includes, starch slurry, polyvinylpyrrolidone,
Hydroxypropyl methyl cellulose etc.；Sweetener includes：Saccharin sodium, aspartame, sucrose, honey element, enoxolone etc.；Flavouring bag
Include：Sweetener and various essence；Preservative includes：Parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzene prick bromine
Ammonium, acetic acid chloroethene are fixed, eucalyptus oil etc.；Matrix includes：PEG6000, PEG4000, insect wax etc..In above-mentioned formulation is realized
Medicine pharmacy, pharmaceutically acceptable other auxiliary materials need to be added when preparing these formulations（Fan Biting《Pharmacy of Chinese materia medica》, Shanghai section
Learn the auxiliary material that each formulation is recorded in publishing house December the 1st edition in 1997）.
Embodiment
Embodiment 1：
Raw material medicine composition is：
Radix Astragali 250g, fruit of glossy privet 200g, ginseng 65g, ganoderma lucidum 65g, curcuma zedoary 132g, rhizoma atractylodis macrocephalae 64g, Sculellaria barbata 128g, gynostemma pentaphylla
256g, Poria cocos 65g, the membrane of a chicken's gizzard 30g, mock-strawberry 128g, bittersweet 128g, oriental wormwood 128g, paniculate swallowwort 128g, ground bettle 20g, long-noded pit viper
Tongue grass 128g.
Preparation method is：
(1) Chinese medicine, is weighed according to bulk drug part by weight, is cleaned；
(2), ginseng, the fruit of glossy privet, 8 times of 70% alcohol refluxs of amount are added to extract 2 times, 3 hours for the first time, second 2 hours, merging carried
Liquid is taken, is filtered, recovery ethanol is extremely standby without alcohol taste, alcohol extracting filtrate and ginseng, fruit of glossy privet residue；
(3), curcuma zedoary, rhizoma atractylodis macrocephalae, paniculate swallowwort, merge extraction volatile oil, carry the oily 8 hours time, the another device of volatile oil is collected, residue and
The aqueous solution is standby；
(4), ground bettle, the membrane of a chicken's gizzard, washing, 60 DEG C of drying, merge with Poria cocos, be ground into 100 mesh powder, radiated in 3KGY60CO-r
It is standby after sterilizing；
(5) income earner in, the Radix Astragali, ganoderma lucidum, oldenlandia diffusa, Sculellaria barbata, gynostemma pentaphylla, mock-strawberry, bittersweet, oriental wormwood, with step (2)
Join, residue after the alcohol extracting of the fruit of glossy privet, and the middle gained curcuma zedoary of step (3), rhizoma atractylodis macrocephalae, paniculate swallowwort propose the residue merging after oil, add 9 times
Measure water, heating decocts 2 times, 2 hours every time, merges decoction liquor, add gained ginseng in step (2), fruit of glossy privet alcohol extracting filtrate and
Step（3）In the aqueous solution, be condensed into the clear cream of relative density 1.25, dry, pulverize, it is standby；
(6) dried cream powder obtained by step (5), is added into 134 grams of starch, with 85% alcohol granulation；
(7), gained volatile oil in step (3) dissolve with 85% ethanol, spray into step (4) it is middle obtained by Poria cocos, ground bettle, in chicken
In the fine powder of gold, mix, with step（6）The particle of middle gained mixes, closed half an hour, loads 1000 capsules and produces.
Embodiment 2：
Raw material medicine composition is：
Radix Astragali 360g, fruit of glossy privet 100g, ginseng 95g, ganoderma lucidum 30g, curcuma zedoary 195g, rhizoma atractylodis macrocephalae 30g, Sculellaria barbata 195g, gynostemma pentaphylla
120g, Poria cocos 95g, the membrane of a chicken's gizzard 15g, mock-strawberry 195g, bittersweet 65g, oriental wormwood 195g, paniculate swallowwort 65g, ground bettle 30g, oldenlandia
Careless 65g.
Preparation method is：
(1) Chinese medicine, is weighed according to bulk drug part by weight, is cleaned；
(2), ginseng, the fruit of glossy privet, 6 times of 90% alcohol refluxs of amount are added to extract 4 hours, extract solution filtering, extract solution reclaims ethanol to nothing
Alcohol taste, alcohol extracting filtrate and ginseng, fruit of glossy privet residue are standby；
(3), curcuma zedoary, rhizoma atractylodis macrocephalae, paniculate swallowwort merge, and add 4 times of amount water extraction volatile oil, carry oily 10 hours time, the another device of volatile oil
Collect, residue and the aqueous solution are standby；
(4), ground bettle, the membrane of a chicken's gizzard, washing, 60 DEG C of drying, merge with Poria cocos, be ground into 100 mesh powder, radiated in 3KGY60CO-r
It is standby after sterilizing；
(5) income earner in, the Radix Astragali, ganoderma lucidum, oldenlandia diffusa, Sculellaria barbata, gynostemma pentaphylla, mock-strawberry, bittersweet, oriental wormwood, with step (2)
Join, residue after the alcohol extracting of the fruit of glossy privet, and the middle gained curcuma zedoary of step (3), rhizoma atractylodis macrocephalae, paniculate swallowwort propose the residue merging after oil, add 7 times
Water is measured, heating decocts 3 times, 1 hour for the first time, second 2 hours, third time 3 hours, merges decoction liquor, adds in step (2)
Gained ginseng, fruit of glossy privet alcohol extracting filtrate and step（3）In the aqueous solution, be condensed into the clear cream of relative density 1.15, dry, powder
It is broken, it is standby；
(6) dried cream powder obtained by step (5), is added into 112 grams of starch, with 78% alcohol granulation；
(7), gained volatile oil in step (3) dissolve with 85% ethanol, spray into step (4) it is middle obtained by Poria cocos, ground bettle, in chicken
In the fine powder of gold, mix, with step（6）The particle of middle gained mixes, and routinely 1000 tablets are made in formulation method.
Embodiment 3：
Raw material medicine composition is：
Radix Astragali 120g, fruit of glossy privet 300g, ginseng 30g, ganoderma lucidum 95g, curcuma zedoary 65g, bighead atractylodes rhizome 90g, Sculellaria barbata 65g, gynostemma pentaphylla 360g,
Poria cocos 30g, the membrane of a chicken's gizzard 45g, mock-strawberry 65g, bittersweet 195g, oriental wormwood 65g, paniculate swallowwort 195g, ground bettle 10g, oldenlandia diffusa
195g。
Preparation method is：
(1) Chinese medicine, is weighed according to bulk drug part by weight, is cleaned；
(2), ginseng, the fruit of glossy privet, 10 times of 50% alcohol refluxs of amount are added to extract 2 times, 3 hours for the first time, second 2 hours, merging carried
Liquid is taken, is filtered, recovery ethanol is extremely standby without alcohol taste, alcohol extracting filtrate and ginseng, fruit of glossy privet residue；
(3), curcuma zedoary, the bighead atractylodes rhizome, paniculate swallowwort merge, and add 10 times of amount water extraction volatile oil, carry oily 6 hours time, the another device of volatile oil
Collect, residue and the aqueous solution are standby；
(4), ground bettle, the membrane of a chicken's gizzard, washing, 60 DEG C of drying, merge with Poria cocos, be ground into 100 mesh powder, radiated in 3KGY60CO-r
It is standby after sterilizing;
(5) income earner in, the Radix Astragali, ganoderma lucidum, oldenlandia diffusa, Sculellaria barbata, gynostemma pentaphylla, mock-strawberry, bittersweet, oriental wormwood, with step (2)
Join, residue after the alcohol extracting of the fruit of glossy privet, and the middle gained curcuma zedoary of step (3), the bighead atractylodes rhizome, paniculate swallowwort propose the residue merging after oil, add 10 times
Water is measured, heating decocts 3 hours, merges decoction liquor, adds gained ginseng, fruit of glossy privet alcohol extracting filtrate and step in step (2)（3）In
The aqueous solution, be condensed into the clear cream of relative density 1.30, dry, pulverize, it is standby；
(6), gained volatile oil in step (3) dissolve with 80% ethanol, spray into step (4) it is middle obtained by Poria cocos, ground bettle, in chicken
In the fine powder of gold, mix, with step（5）The dried cream powder of middle gained, routinely formulation method 1000 pills are made.
Experimental example：
To confirm the therapeutic effect of medicine of the present invention, with the Capsule content extract solution as made from embodiment 1（Hereinafter referred to as
DME25）, carried out tests below research：
1. material and method：
1.1 DME25 preparation：
The Capsule content as made from embodiment 1 is added to DMSO（Dimethyl sulfoxide (DMSO)）In solution, 4 C, 100rpm, rotation
Instrument concussion processing 12 hours；Solution centrifuges 20 minutes under the conditions of 4 C, rotating speed 15000g, then takes supernatant, 0.20 μm of filter
DME25 is made after membrane filtration, 4 C are saved backup.
The foundation of 1.2 chemicals endothelial cell injury models and pharmaceutical intervention experiment：
By the endothelial cell of identical quantity（Human umbilical vein endothelial cell line HUVEC, human vascular endothelial system HECV）Connect respectively
Kind into 25 square centimeters or so of Tissue Culture Dish, be placed in 37 DEG C, in 5% CO2 incubators culture until cell fusion 80% is left
The right side, reject nutrient solution, experiment packet are as follows：1. blank control group：With normal nutrient solution culture HUVEC or HECV；2. DIET is damaged
Hinder group：With containing chemicals（DIET）Nutrient solution culture HUVEC or HECV；3. pharmaceutical intervention group：First with the training containing DME25
Nutrient solution preincubate 8 hours, discards nutrient solution, with containing chemicals（DIET）With DME25 nutrient solution culture HUVEC or
HECV.Each group is incubated 8 hours.
The foundation of 1.3 mechanical damage endothelial cell models and pharmaceutical intervention experiment：
By the endothelial cell of identical quantity（Human umbilical vein endothelial cell line HUVEC, human vascular endothelial system HECV）Connect respectively
Kind into 25 square centimeters or so of Tissue Culture Dish, be placed in 37 DEG C, in 5% CO2 incubators culture until cell fusion 80% is left
It is right.Reject nutrient solution, experiment packet are as follows：1. blank control group：With normal nutrient solution culture HUVEC or HECV；2. machinery damage
Hinder group：After damaging monolayer endothelial cell using more pipette stations, with normal nutrient solution culture HUVEC or HECV；3. medicine is done
Pre- group：First with the nutrient solution preincubate 8 hours containing DME25, nutrient solution is discarded, it is thin to damage individual layer endothelium using more pipette stations
After born of the same parents, with nutrient solution culture HUVEC or HECV containing DME25.Each group is incubated 8 hours.
2. Testing index
The observation of 2.1 each group endothelial cell morphologies
The change of each group endothelial cell morphology after chemicals and mechanical damage endothelial cell is observed using inverted microscope.
2.2 methods detection each group cells survival activity
After experiment terminates, cell culture supernatant is removed, adds the μ L of serum-free basic culture solution 100 containing CCK-8（CCK-8
Solution:Serum-free basic culture solution=1:10）, 37 DEG C are placed in, continues to be incubated 1-4h, ELIASA detection in 5% CO2 incubators
OD values at 450 nm wavelength.Using blank control group OD values as reference, cell survival rate is with each group OD values and blank control group OD
The ratio of value represents.
2.3 each group cell culture supernatant nitric oxides（Nitric oxide, NO）And endothelin -1（endothelin-
1, ET-1）The change of content
After experiment terminates, each group cell culture supernatant is collected, after 1000 rpm centrifuge 2 min, cell fragment is removed, takes supernatant
Liquid.Using nitrate reductase method and enzyme linked immunosorbent assay（Enzyme linked immunosorbent assay, ELISA
Method）NO and ET-1 contents in cell supernatant are detected respectively, and laboratory operating procedures are carried out in strict accordance with specification.
2.4 genechip detection
RNA extraction：After experiment terminates, culture medium is absorbed, PBS 2 times, then add Trizol lysates（5x 105~
10 cells of x 105 add 1mL lysates）Cell lysis, gently rubs shake, cracks 5 min at room temperature, lysate is transferred to
In 1.5 mL EP pipes, add 0.2 mL chloroforms and shaken on turbula shaker 30 seconds, place 5 min on ice.Refrigerated centrifuge 4
DEG C, 12000 rpm centrifuge 15 min, and careful upper strata supernatant of drawing is moved in another 1.5 mL EP pipe, added isometric
Isopropanol mix, 2 h are stood in -20 DEG C of refrigerators.4 DEG C of refrigerated centrifuge again, 12000 rpm, 15 min are centrifuged, are discarded
Clearly, after adding the mixing of 1/3 volume absolute ethyl alcohol, 4 DEG C of refrigerated centrifuge, 12000 rpm, centrifuge 15 min again, absorb clean
After supernatant, precipitation is washed 3 times with RNA Wash Buffer, is added the treated deionized water dissolvings of 20 μ L DEPC, is obtained
Precipitated to total serum IgE.Pass through the purity and quantity of gel imaging and spectrophotometric determination nucleic acid.
MRNA separation and cDNA amplifications：Using micro- magnetic bead mRNA extracts kits, the mRNA in total serum IgE is separated, is used
bioanalyser 2100（Agilent）Detect ribosomes degraded.Pass through ion total serum IgE kit V2（Life
Technologies）Generate RNA fragment libraries（About 150~200bp）, these fragments be incorporated into cDNA synthesis joint on.Profit
CDNA amplifications are carried out with the random RNA5' and 3' primers of ionic, pass through 2100 analysing amplified cDNA of bioanalyser piece
Duan great little and peak concentration.
The preparation of template and RNA sequencings：Utilize the kit v3 (Life of Ion PI template OT2 200
Technologies) kit is carried out further clone's amplification to cDNA fragment libraries by suspension PCR and forms ion microballoon
Particle (ISPs).Reclaimed and be enriched with by the Ion OneTouch ES systems ISP positive to template after PCR, and go unless
The positive ISP of template.The ISP of enrichment is sequenced using kit specification.In Torrent Suite version after sequencing
Base determination, joint finishing, bar code deconvolution and calibration are carried out by STAR RNA-seq calibration inserts on 3.6, and according to people
Genoid group（hg19）Form export data as BAM files.
3rd, statistical analysis
3.1 use the statistical analysis softwares of SPSS 19.0, and all continuous datas use mean ± standard deviation（±s）Represent.Examine first
Test whether data meet normality distribution, meet normal distribution uses one-way analysis of variance (One-Way ANOVA), if side
It is poor neat, compare two-by-two using least significant difference between group（Least significant difference, LSD）If variance is not
Qi Ze is examined using Dunnett`s T3, P<0.05 is that difference is statistically significant, P<0.01 is that difference has conspicuousness statistics
Meaning.
The result of 3.2 gene expressions is represented with mean ± standard deviation, statistical analysis is examined with t between group.
4th, result
The form of 4.1 each group endothelial cells compares
Blank control group HUVEC/HECV karyomorphisms are regular, edge clear, it is seen that cell division is bred；DIET damages group and
Mechanical damage group karyopyknosis, marginalisation, nucleus volume reduce, and karyorrhexis, produce apoptotic body；It is interior after pharmaceutical intervention
Chrotoplast edge is more visible, and karyopycnosis, marginalisation phenomenon postpone, lesser extent, and visible cell division growth.
4.2 chemicals DIET are damaged and the change of mechanical damage endothelial cell each group existence activity
4.2.1 the change of DIET endothelial cell injuries each group existence activity
Compared with blank control group, DIET damage group HUVEC/HECV endothelial cells existence activity reduces（P<0.01）；With DIET
Damage group is compared, the significantly rise of pharmaceutical intervention group endothelial cell existence activity（P<0.01）.（It is shown in Table 1）
4.2.2 the change of mechanical damage endothelial cell each group existence activity
Compared with blank control group, after mechanical damage HUVEC/HECV endothelial cells, endothelial cell existence activity is obvious to be reduced（P<
0.01）；Compared with mechanical damage group, pharmaceutical intervention group endothelial cell existence activity is significantly raised（P<0.01）.（It is shown in Table 2）
4.3 chemicals DIET and mechanical damage endothelial cell each group NO and ET-1 level change
4.3.1 the change of DIET endothelial cell injuries each group supernatant NO and ET-1 content
Compared with blank control group, DIET damage group supernatants NO is horizontal to be reduced（P<0.05）, ET-1 levels are significantly raised（P<
0.01）；Compared with DIET damage groups, pharmaceutical intervention group supernatant NO contents significantly raise（P<0.01）, ET-1 contents significantly drop
It is low（P<0.01）.（It is shown in Table 3）
4.3.2 the change of mechanical damage endothelial cell each group supernatant NO and ET-1 content
Compared with blank control group, after mechanical damage endothelial cell, NO is horizontal to be reduced（P<0.05, P<0.01）, ET-1 is horizontal to be risen
It is high（P<0.05, P<0.01）；Compared with mechanical damage group, pharmaceutical intervention group supernatant NO contents are significantly raised（P<0.01）, ET-
1 content significantly reduces（P<0.01）.（It is shown in Table 4）
4.4 genechip detection results
4.4.1 HUVEC/HECV cells CCL families factor expression situation
As shown in table 5, CCL28, CCL3, CCL5, CCL21, CCL23, CCL27 high level expression in HUVEC cells, CCL8,
CCL13 also has higher level expression；CCL3L3, CCL28 high level expression in HECV cells, CCL1, CCL3, CCL5, CCL8,
CCL23 also has higher level expression.
4.4.2 chemicals DIET/ mechanical damages HECV endothelial cells each group CCL families factor expression
As shown in table 6, chemicals DIET processing can induce HECV endothelial cells CXCL1, CCL2, CCL3, CCL5, CCL7,
CCL27, CXCL12 abnormal expression reduce, the rise of CCL14, CCL15, CCL21, CCL23 abnormal expression（P<0.05, P<0.01）；
Medicine DME25 intervenes the expression that can improve CXCL1, CCL2, CCL3, CCL5, CCL7, CCL27, CXCL12（P<0.05, P<
0.01）, reduce CCL14, CCL15, CCL21, CCL23 expression（P<0.05, P<0.01）.
As shown in table 7, mechanical damage can cause CXCL1, CXCL2, CXCL6, CXCL16, CSCL6, CCL2 abnormal expression to raise（P
<0.05, P<0.01）, the reduction of CCL14, CCL19, CCL28, CCL3, CCL5, CCL23 abnormal expression（P<0.05, P<0.01）；Medicine
Thing DME25 intervenes the expression that can significantly reduce CXCL1, CXCL2, CXCL6, CXCL16, CSCL6, CCL2（P<0.05, P<
0.01）, raising CCL14, CCL19, CCL28, CCL3, CCL5, CCL23 expression（P<0.05, P<0.01）.
4.4.3 chemicals DIET/ mechanical damages HECV endothelial cells each group chemokine receptor expression
As shown in table 8, chemicals DIET can increase HECV endothelial cells CCR2 expression, reduce CCR7, CCRL1,
CXCR4, CXCR6, CXCR7 and CCR5 are expressed（P<0.05, P<0.01）.Medicine DME25, which intervenes, can significantly reduce CCR2 expression,
Increase CCR5, CCRL1, CXCR4, CXCR7, CCR6 expression（P<0.05, P<0.01）.
As shown in table 9, in HECV cells, mechanical damage causes CXCR4, CCRL1 to lower, CCR2 up-regulations（P<0.05）.
DME25 lowers CXCR4, CCR2 expression, up-regulation CCRL1 expression after intervening（P<0.05）.
5th, conclusion
Chemical irritants diethylstilbestrol（DIET）With mechanical damage method can endothelial cell injury, destroy endothelial cell shape
State, endothelial cell existence activity is reduced, causes endothelial cell karyopyknosis, apoptosis, suppresses endothelial cell growth propagation.Simultaneously
DIET and mechanical damage endothelial cell method can reduce endothelial cell NO secretions, increase ET-1 expression, endothelial cells secrete function
Unbalance, endothelial cell correlation factor CCL family's factors and chemokine receptors are not normal.After DME25 intervenes, endothelial cell can be protected
Form, endothelial cell existence activity is improved, promotion endothelial cell growth propagation, increase NO secretions, ET-1 is reduced and expresses, in improvement
Skin cell secretion function, adjust CCL family's factors and chemokine receptor expression.
Claims (10)
1. application of a kind of Chinese medicine composition in the medicine for preparing protection endothelial cell, it is characterised in that be following weight part ratio
Made of the bulk drug of example：
Radix Astragali 120-360, fruit of glossy privet 100-300, ginseng 30-95, ganoderma lucidum 30-95, curcuma zedoary 65-195, bighead atractylodes rhizome 30-90, half
Lotus 65-195, gynostemma pentaphylla 120-360, Poria cocos 30-95, the membrane of a chicken's gizzard 15-45, mock-strawberry 65-195, bittersweet 65-195, oriental wormwood 65-195
Paniculate swallowwort 65-195 ground bettle 10-30 oldenlandia diffusas 65-195.
2. application according to claim 1, it is characterised in that be made up of the bulk drug of following parts by weight:
The Radix Astragali 120, the fruit of glossy privet 300, ginseng 30, ganoderma lucidum 95, curcuma zedoary 65, the bighead atractylodes rhizome 90, Sculellaria barbata 65, gynostemma pentaphylla 360, Poria cocos 30,
The membrane of a chicken's gizzard 45, mock-strawberry 65, bittersweet 195, oriental wormwood 65, paniculate swallowwort 195, ground bettle 10, oldenlandia diffusa 195.
3. application according to claim 1, it is characterised in that be made up of the bulk drug of following parts by weight:
The Radix Astragali 360, the fruit of glossy privet 100, ginseng 95, ganoderma lucidum 30, curcuma zedoary 195, the bighead atractylodes rhizome 30, Sculellaria barbata 195, gynostemma pentaphylla 120, Poria cocos
95th, the membrane of a chicken's gizzard 15, mock-strawberry 195, bittersweet 65, oriental wormwood 195, paniculate swallowwort 65, ground bettle 30, oldenlandia diffusa 65.
4. application according to claim 1, it is characterised in that be made up of the bulk drug of following parts by weight:
The Radix Astragali 250, the fruit of glossy privet 200, ginseng 65, ganoderma lucidum 65, curcuma zedoary 132, the bighead atractylodes rhizome 64, Sculellaria barbata 128, gynostemma pentaphylla 256, Poria cocos
65th, the membrane of a chicken's gizzard 30, mock-strawberry 128, bittersweet 128, oriental wormwood 128, paniculate swallowwort 128, ground bettle 20, oldenlandia diffusa 128.
5. according to the application described in claim any one of 1-4, it is characterised in that the active component of the Chinese medicine composition by with
Lower step is made:
(1) Chinese medicine, is weighed according to bulk drug part by weight, is cleaned；
(2), the fruit of glossy privet, people participate in 6-10 times and measure 50-90% ethanol extraction 1-3 times, each 1-4 hours, merge extract solution, filter,
Filtrate recycling ethanol is extremely standby without alcohol taste, filtrate and the dregs of a decoction；
(3), curcuma zedoary, the bighead atractylodes rhizome, paniculate swallowwort add 4-8 times to measure water extraction volatile oil, collect volatile oil, and another device is collected, residue and water-soluble
Liquid is standby;
(4), ground bettle, the membrane of a chicken's gizzard, Poria cocos are ground into fine powder；
(5) income earner in, the Radix Astragali, ganoderma lucidum, oldenlandia diffusa, Sculellaria barbata, gynostemma pentaphylla, mock-strawberry, bittersweet, oriental wormwood, with step (2)
Join, residue after the alcohol extracting of the fruit of glossy privet, and the middle gained curcuma zedoary of step (3), the bighead atractylodes rhizome, paniculate swallowwort propose residue merging after oil, add 7-10 times
Water is measured, heating decocts 1-3 times, each 1-3 hours, merges decoction liquor, adds gained ginseng in step (2), fruit of glossy privet alcohol extracting filter
Liquid and step（3）In the aqueous solution, be concentrated into decoction 65 DEG C survey when relative density be 1.15-1.30, dry, pulverize, it is standby;
Step（4）Gained comminuted powder, step（3）Gained volatile oil and step（5）The dried cream powder of gained collectively forms the Chinese medicine group
The active component of compound.
6. according to the application described in claim any one of 1-4, it is characterised in that the pharmaceutical dosage form is capsule, tablet, dissipated
Agent, oral liquid, pill, tincture, syrup, suppository, gel, spray or injection.
7. application according to claim 6, it is characterised in that the preparation method of the medicine capsule is by following steps
It is made：
(1) Chinese medicine, is weighed according to bulk drug part by weight, is cleaned；
(2), ginseng, the fruit of glossy privet, 8 times of 70% alcohol refluxs of amount are added to extract 2 times, 3 hours for the first time, second 2 hours, merging carried
Liquid is taken, is filtered, recovery ethanol is extremely standby without alcohol taste, filtrate and ginseng fruit of glossy privet residue;
(3), curcuma zedoary, the bighead atractylodes rhizome, paniculate swallowwort, merge extraction volatile oil, carry oily time 6-12 hours, the another device of volatile oil is collected, residue
And the aqueous solution is standby;
(4), ground bettle, the taste animal drugs of the membrane of a chicken's gizzard two, washing, 60 DEG C of drying, merge with Poria cocos, 100 mesh powder are ground into, after sterilizing
It is standby;
(5) income earner in, the Radix Astragali, ganoderma lucidum, oldenlandia diffusa, Sculellaria barbata, gynostemma pentaphylla, mock-strawberry, bittersweet, oriental wormwood, with step (2)
Join, residue after the alcohol extracting of the fruit of glossy privet, and the middle gained curcuma zedoary of step (3), the bighead atractylodes rhizome, paniculate swallowwort propose residue merging after oil, add 9 times of amounts
Water, heating decoct 2 times, 2 hours every time, merge decoction liquor, add gained ginseng, fruit of glossy privet alcohol extracting filtrate and step in step (2)
Suddenly（3）Obtained aqueous solution, relative density 1.20-1.25 clear cream is condensed into, dry, pulverize, get dry extract powder；By gained dried cream powder
Add appropriate pharmaceutically acceptable auxiliary material granulation；
(6), gained volatile oil in step (3) is sprayed into the fine powder of the middle gained Poria cocos of step (4), ground bettle, the membrane of a chicken's gizzard, mixed
It is even, with step（5）The particle of middle gained mixes, closed half an hour, encapsulated to produce.
8. according to the application described in claim any one of 1-4, it is characterised in that it is described protection endothelium for confrontation endothelial cell by
The reduction of Secretion of Nitric Oxide after damage, the rise of endothelin -1 after confrontation endothelial cell is impaired.
9. according to the application described in claim 1-4, it is characterised in that the protection endothelial cell is regulation damaged endothelial cells
Cell chemotactic factor and acceptor expression.
10. according to the application described in claim 1-4, it is characterised in that the endothelial cell be human umbilical vein endothelial cell line or
Human vascular endothelial system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610323079.0A CN107375821A (en) | 2016-05-17 | 2016-05-17 | A kind of Chinese medicine composition is preparing the application in protecting vascular endothelial cell medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610323079.0A CN107375821A (en) | 2016-05-17 | 2016-05-17 | A kind of Chinese medicine composition is preparing the application in protecting vascular endothelial cell medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107375821A true CN107375821A (en) | 2017-11-24 |
Family
ID=60337704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610323079.0A Pending CN107375821A (en) | 2016-05-17 | 2016-05-17 | A kind of Chinese medicine composition is preparing the application in protecting vascular endothelial cell medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107375821A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110856741A (en) * | 2018-08-21 | 2020-03-03 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating diarrhea |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417907A (en) * | 2012-05-26 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of traditional Chinese medicine composition in preparation of drug used for inhibiting angiogenesis |
| CN103830662A (en) * | 2012-05-26 | 2014-06-04 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of drug for inhibiting rheumatoid arthritis angiogenesis |
-
2016
- 2016-05-17 CN CN201610323079.0A patent/CN107375821A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417907A (en) * | 2012-05-26 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of traditional Chinese medicine composition in preparation of drug used for inhibiting angiogenesis |
| CN103830662A (en) * | 2012-05-26 | 2014-06-04 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of drug for inhibiting rheumatoid arthritis angiogenesis |
Non-Patent Citations (3)
| Title |
|---|
| 刘建勋等: "《科技发展与成就：中国中医研究院西苑医院五十年历程》", 31 December 2005, 中医古籍出版社 * |
| 孔祥英等: "《临床心血管病诊疗学》", 31 December 2012, 科学技术文献出版社 * |
| 张水艳等: "养正消积胶囊辅助介入化疗治疗原发性肝癌的随机双盲多中心临床研究", 《疑难病杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110856741A (en) * | 2018-08-21 | 2020-03-03 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating diarrhea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104039319B (en) | For treating HCV composition and method | |
| CN111888435B (en) | Anti-coronavirus traditional Chinese medicine composition and application thereof in treating inflammation | |
| JP5057987B2 (en) | Herbal composition PHY906 and its use in chemotherapy | |
| JP5064630B2 (en) | Herbal composition PHY906 and its use in chemotherapy | |
| CN107635566A (en) | Treat the composition and method of HBV infection | |
| WO2007007993A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract | |
| TWI284040B (en) | Herbal compositions for treating immunological disorders | |
| CN103848914B (en) | A kind of the Bufrudin polypeptide and preparation method thereof and purposes of tool anticoagulating active | |
| CN107375821A (en) | A kind of Chinese medicine composition is preparing the application in protecting vascular endothelial cell medicine | |
| Ravi | Procyanidin B2 of Cassia fistula a potent inhibitor of COVID19 protease: A molecular dynamic simulation analysis | |
| CN101304756B (en) | Herbal composition for inflammatory disorders | |
| US20100074975A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract | |
| US20240024465A1 (en) | Allergen preparation | |
| KR102270850B1 (en) | Pharmaceutical composition for treating or preventing Arthritis | |
| US9789158B2 (en) | Applications of recombined Ganoderma lucidum immunoregulation protein in preparing drugs for treating tissue fibrosis | |
| KR20230005187A (en) | Methods for Treating Inflammatory and Fibrous Diseases and Disorders | |
| Dwivedi et al. | Comparative efficacy of Liv. 52 and Andrographis paniculata Nees in experimental liver damage in rabbits | |
| EP3257518A1 (en) | A pharmaceutical composition for treating or alleviating autoimmune-related diseases and use of an acitive ingredient in the pharmaceutical composition | |
| CN103239432A (en) | Compound ambroxol hydrochloride composition granule and preparation method thereof | |
| CN108619179A (en) | Geranium extract and its medical usage | |
| TWI741190B (en) | Cordyceps militaris compound for improving respiratory diseases | |
| US20240226214A1 (en) | Methods for treating inflammatory and fibrotic diseases and disorders | |
| KR102609822B1 (en) | Peptide having anti-inflammatory activity and use thereof | |
| KR20120053395A (en) | Pharmaceutical composition for treating asthma comprising 4-phenylbutyric acid or pharmaceutically acceptable salts thereof | |
| Murthy et al. | Therapeutic properties of processed aqueous extract of Asteracantha longifolia in the human |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |